Evidence map›Paper›PMID 33037033›Full record

ReviewESMO open2020

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.

Patrick W Burke, Dieter Hoelzer, Jae H Park, Kjeld Schmiegelow, Dan Douer

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESMO open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Asperginase-based chemotherapy regimen for acute lymphoblastic leukemia: A cohort study with promising outcomes on adults.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Patrick W BurkeDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: pwburke@med.umich.edu.
Dieter HoelzerInternal Medicine, Onkologikum Frankfurt, Frankfurt, Germany.
Jae H ParkLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Kjeld SchmiegelowDepartment of Pediatrics and Adolescent Medicine, Juliane Marie Center, Rigshospitalet University Hospital, and Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Dan DouerJane Anne Nohle Division of Hematology, University of Southern California, Los Angeles, California, USA.
Memorial Sloan Kettering Cancer Center · USUniversity of Copenhagen · DKUniversity of Michigan–Ann Arbor · USUniversity of Southern California · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

With recent prospective clinical trials that used paediatric regimens with multiple doses of pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly improved survival compared with historical data with regimens that used less asparaginase, PEG asparaginase is increasingly being used in the treatment of adult acute lymphoblastic leukaemia (ALL). However, administering asparaginase still comes with its challenges, especially in adult patients. Therefore, it is important to understand how to manage its toxicities properly. An expert group met in November 2019 in London to discuss recent data of paediatric as well as adult studies using paediatric regimens with regard to the best management of several key toxicities that can occur in adults treated with asparaginase including hepatotoxicity, pancreatitis, hypertriglyceridaemia, thrombosis and hypersensitivity. Several recommendations were made for each one of these toxicities, with the goal of safe administration of the drug and to educate clinicians when the drug can be continued despite side effects.

Indexed as

Antineoplastic AgentsPancreatitisPrecursor Cell Lymphoblastic Leukemia-LymphomaThrombosisAdultAsparaginaseChildHumansPractice Guidelines as TopicAntineoplastic AgentsAsparaginaseacute lymphoblastic leukaemiaasparaginasehypersensitivitypancreatitistherapeutic drug monitoringthrombosistoxicities

Identifiers

PMID33037033
PMCPMC7549445
OpenAlexW3091926417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.